BioCentury | Dec 19, 2019
Finance

Boehringer deal, clinical milestones support Bridge IPO

...across seven deals. Bridge is the second Korean IPO to price in 2H19. In September, OliPass Corp....
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...XBI) -13% 6% Table: IPO performance Company Date Raised Post-$ 9/30 mcap Mcap chg % OliPass Corp....
BioCentury | Nov 3, 2014
Company News

OliPass, Bristol-Myers deal

...discover and develop antisense medicines based on OliPass's peptide nucleic acid technology against undisclosed targets. OliPass...
...objectives. For each product BMS licenses, OliPass will be eligible to receive milestones and royalties. OliPass...
...specific targets or financial terms, and OliPass could not be reached in time for publication. OliPass Corp....
BioCentury | Oct 31, 2014
Company News

BMS and OliPass partner to develop PNA-based therapeutics

...partnered to develop therapeutics against multiple targets using OliPass' peptide nucleic acid (PNA) technology platform. OliPass...
...BMS declined to disclose information regarding specific compounds and targets, but said the partnership with OliPass...
...range of targets "consistent with our R&D strategy" including its interest in genetically defined diseases. OliPass...
Items per page:
1 - 4 of 4
BioCentury | Dec 19, 2019
Finance

Boehringer deal, clinical milestones support Bridge IPO

...across seven deals. Bridge is the second Korean IPO to price in 2H19. In September, OliPass Corp....
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...XBI) -13% 6% Table: IPO performance Company Date Raised Post-$ 9/30 mcap Mcap chg % OliPass Corp....
BioCentury | Nov 3, 2014
Company News

OliPass, Bristol-Myers deal

...discover and develop antisense medicines based on OliPass's peptide nucleic acid technology against undisclosed targets. OliPass...
...objectives. For each product BMS licenses, OliPass will be eligible to receive milestones and royalties. OliPass...
...specific targets or financial terms, and OliPass could not be reached in time for publication. OliPass Corp....
BioCentury | Oct 31, 2014
Company News

BMS and OliPass partner to develop PNA-based therapeutics

...partnered to develop therapeutics against multiple targets using OliPass' peptide nucleic acid (PNA) technology platform. OliPass...
...BMS declined to disclose information regarding specific compounds and targets, but said the partnership with OliPass...
...range of targets "consistent with our R&D strategy" including its interest in genetically defined diseases. OliPass...
Items per page:
1 - 4 of 4